TY - JOUR
T1 - Drugs and the liver
T2 - Advances in metabolism, toxicity, and therapeutics
AU - Buratti, Silvia
AU - Lavine, Joel E.
PY - 2002/10
Y1 - 2002/10
N2 - Biotransformation of drugs is one of the major functions of liver. Hepatic drug metabolism develops early in organogenesis and continues in postnatal life through puberty. Genetic and developmental studies on hepatic drug metabolism show that immaturity, polymorphisms, and altered balance of different hepatic enzymatic activities affect pharmacologic inactivation and alter the risk of toxic effects of drugs on the hepatic parenchyma. Although drug-induced liver disease is less common in children, several reports of hepatotoxicity are published every year. Furthermore, the increasing use of nonregulated remedies (eg, herbal preparations or recreational drugs) increases the risk of unpredictable and potentially severe reactions. Many significant advances in the treatment of hepatic diseases have been achieved recently. However, differences in clinical features, natural history, and response to treatment between children and adults require evaluation of new therapeutic options in focused pediatric clinical trials.
AB - Biotransformation of drugs is one of the major functions of liver. Hepatic drug metabolism develops early in organogenesis and continues in postnatal life through puberty. Genetic and developmental studies on hepatic drug metabolism show that immaturity, polymorphisms, and altered balance of different hepatic enzymatic activities affect pharmacologic inactivation and alter the risk of toxic effects of drugs on the hepatic parenchyma. Although drug-induced liver disease is less common in children, several reports of hepatotoxicity are published every year. Furthermore, the increasing use of nonregulated remedies (eg, herbal preparations or recreational drugs) increases the risk of unpredictable and potentially severe reactions. Many significant advances in the treatment of hepatic diseases have been achieved recently. However, differences in clinical features, natural history, and response to treatment between children and adults require evaluation of new therapeutic options in focused pediatric clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=0036785453&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036785453&partnerID=8YFLogxK
U2 - 10.1097/00008480-200210000-00007
DO - 10.1097/00008480-200210000-00007
M3 - Article
C2 - 12352255
AN - SCOPUS:0036785453
VL - 14
SP - 601
EP - 607
JO - Current Opinion in Pediatrics
JF - Current Opinion in Pediatrics
SN - 1040-8703
IS - 5
ER -